CN102762541B - 作为趋化因子受体的调节剂的二氮杂*衍生物 - Google Patents
作为趋化因子受体的调节剂的二氮杂*衍生物 Download PDFInfo
- Publication number
- CN102762541B CN102762541B CN201080047338.2A CN201080047338A CN102762541B CN 102762541 B CN102762541 B CN 102762541B CN 201080047338 A CN201080047338 A CN 201080047338A CN 102762541 B CN102762541 B CN 102762541B
- Authority
- CN
- China
- Prior art keywords
- oxo
- spiro
- methyl
- aza
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(*CC1)*1=O Chemical compound *C(*CC1)*1=O 0.000 description 2
- ZBANUGSWAVZHSH-RMSVRTADSA-N CC(C(N(CC1)[C@@H](CCC(N(CCC23CC2)C[C@H]3O)=O)C(OC)=O)=O)N1C(Nc1ccc(C(F)(F)F)c(C(F)(F)F)c1)=O Chemical compound CC(C(N(CC1)[C@@H](CCC(N(CCC23CC2)C[C@H]3O)=O)C(OC)=O)=O)N1C(Nc1ccc(C(F)(F)F)c(C(F)(F)F)c1)=O ZBANUGSWAVZHSH-RMSVRTADSA-N 0.000 description 1
- XXKUUIQIKPEEOT-BQYQJAHWSA-N CN(C)C(CC(C(OC)=O)N(CCN(CC1)C(/C=C/c2cc(Cl)ccc2)=O)C1=O)=O Chemical compound CN(C)C(CC(C(OC)=O)N(CCN(CC1)C(/C=C/c2cc(Cl)ccc2)=O)C1=O)=O XXKUUIQIKPEEOT-BQYQJAHWSA-N 0.000 description 1
- NTEMMNIBNYEEKT-DGLRVSLGSA-N C[C@@H](C(N(CC1)[C@@H](CCC(N(CCC23CC2)C[C@H]3O)=O)C(NC)OC)=O)N1C(Nc1cc(Cl)c(C(F)(F)F)cc1)=O Chemical compound C[C@@H](C(N(CC1)[C@@H](CCC(N(CCC23CC2)C[C@H]3O)=O)C(NC)OC)=O)N1C(Nc1cc(Cl)c(C(F)(F)F)cc1)=O NTEMMNIBNYEEKT-DGLRVSLGSA-N 0.000 description 1
- CXLHVDCCCSMLMX-ZOCIIQOWSA-N C[C@@H](C(N(CC1)[C@@H](CCC(N(CCC23CC2)C[C@H]3O)=O)C(O)=O)=O)N1C(Nc1cc(Cl)c(C(F)(F)F)cc1)=O Chemical compound C[C@@H](C(N(CC1)[C@@H](CCC(N(CCC23CC2)C[C@H]3O)=O)C(O)=O)=O)N1C(Nc1cc(Cl)c(C(F)(F)F)cc1)=O CXLHVDCCCSMLMX-ZOCIIQOWSA-N 0.000 description 1
- PKJDVBFUJALTOM-RYGJVYDSSA-N C[C@@H](C(N(CC1)[C@@H](CCC(N(CCC23CC2)C[C@H]3O)=O)C(OC)=O)=O)N1C(Nc1cc(Cl)c(C(F)(F)F)cc1)=O Chemical compound C[C@@H](C(N(CC1)[C@@H](CCC(N(CCC23CC2)C[C@H]3O)=O)C(OC)=O)=O)N1C(Nc1cc(Cl)c(C(F)(F)F)cc1)=O PKJDVBFUJALTOM-RYGJVYDSSA-N 0.000 description 1
- SWWZQSGZATUIOC-AWEZNQCLSA-N C[C@@H](C(N(CCC(N1CCCCC1)=O)CC1)=O)N1C(Nc(cc1)cc(Cl)c1Cl)=O Chemical compound C[C@@H](C(N(CCC(N1CCCCC1)=O)CC1)=O)N1C(Nc(cc1)cc(Cl)c1Cl)=O SWWZQSGZATUIOC-AWEZNQCLSA-N 0.000 description 1
- IUNCMBOVMROGNB-FXAWDEMLSA-N OC[C@H](CCC(N(CCC12CC1)C[C@H]2O)=O)N(CCN(CC1)c2cc(Cl)c(C(F)(F)F)cc2)C1=O Chemical compound OC[C@H](CCC(N(CCC12CC1)C[C@H]2O)=O)N(CCN(CC1)c2cc(Cl)c(C(F)(F)F)cc2)C1=O IUNCMBOVMROGNB-FXAWDEMLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09173682.7 | 2009-10-21 | ||
| EP09173682 | 2009-10-21 | ||
| PCT/EP2010/065579 WO2011048032A1 (en) | 2009-10-21 | 2010-10-18 | Diazepam derivatives as modulators of chemokine receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102762541A CN102762541A (zh) | 2012-10-31 |
| CN102762541B true CN102762541B (zh) | 2016-03-16 |
Family
ID=43087104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080047338.2A Expired - Fee Related CN102762541B (zh) | 2009-10-21 | 2010-10-18 | 作为趋化因子受体的调节剂的二氮杂*衍生物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8445674B2 (enExample) |
| EP (1) | EP2491022B1 (enExample) |
| JP (1) | JP5654027B2 (enExample) |
| KR (1) | KR20120070609A (enExample) |
| CN (1) | CN102762541B (enExample) |
| AU (1) | AU2010309920A1 (enExample) |
| BR (1) | BR112012009661A2 (enExample) |
| CA (1) | CA2776914A1 (enExample) |
| ES (1) | ES2531986T3 (enExample) |
| IL (1) | IL218795A0 (enExample) |
| IN (1) | IN2012DN03045A (enExample) |
| MX (1) | MX2012004112A (enExample) |
| WO (1) | WO2011048032A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2764840T3 (es) | 2015-01-28 | 2020-06-04 | Univ Bordeaux | Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica |
| AU2016305590A1 (en) | 2015-08-13 | 2018-02-15 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds |
| CN105906553B (zh) * | 2016-04-21 | 2019-01-29 | 重庆威尔德·浩瑞医药化工有限公司 | 一种n-苄基-4-甲基哌啶-3-酮盐酸盐的合成方法 |
| CN107216335B (zh) * | 2017-06-29 | 2019-04-30 | 上海药明康德新药开发有限公司 | 一种叔丁基1-(羟甲基)-3-氧杂-9-氮杂螺[5.5]十一烷-9-甲酸基酯制法 |
| KR101938991B1 (ko) | 2017-09-25 | 2019-01-15 | 강원대학교산학협력단 | 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물 |
| CN111423454B (zh) * | 2020-04-24 | 2021-06-22 | 苏州大学 | 哌嗪类化合物及其在制备趋化因子受体ccr2拮抗剂中的应用 |
| CN113200997B (zh) * | 2021-05-07 | 2023-10-03 | 上海合全医药有限公司 | 2,5-二氧杂-8-氮杂螺[3.5]壬烷及其盐的合成方法 |
| EP4382529A1 (en) | 2022-12-07 | 2024-06-12 | Bayer Consumer Care AG | A process for preparing pure (3s)-pyrrolidin-3-ol and pure (3s)-pyrrolidin-3-ol hydrochloride |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005123697A1 (ja) * | 2004-06-21 | 2005-12-29 | Astellas Pharma Inc. | キナゾリン誘導体 |
| CN1871222A (zh) * | 2003-10-24 | 2006-11-29 | 霍夫曼-拉罗奇有限公司 | Ccr3受体拮抗剂 |
| WO2009010429A2 (en) * | 2007-07-19 | 2009-01-22 | F. Hoffmann-La Roche Ag | Novel heterocyclyl compounds and their use as chemokine antagonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0012240D0 (en) | 2000-05-19 | 2000-07-12 | Merck Sharp & Dohme | Therapeutic agents |
| US20080119471A1 (en) * | 2004-02-24 | 2008-05-22 | Ulrike Kaufmann | Piperazine urea derivatives for the treatment of endometriosis |
| WO2007034282A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists |
| US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
| JP2010208945A (ja) * | 2007-06-01 | 2010-09-24 | Mitsubishi Tanabe Pharma Corp | 複素環化合物 |
| BRPI0916574A2 (pt) | 2008-07-28 | 2015-11-10 | Hoffmann La Roche | derivados de diazepano e piperazina moduladores de receptores de quiomiocinas |
| WO2011002067A1 (ja) * | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
-
2010
- 2010-10-11 US US12/901,592 patent/US8445674B2/en not_active Expired - Fee Related
- 2010-10-18 AU AU2010309920A patent/AU2010309920A1/en not_active Abandoned
- 2010-10-18 CA CA2776914A patent/CA2776914A1/en not_active Abandoned
- 2010-10-18 CN CN201080047338.2A patent/CN102762541B/zh not_active Expired - Fee Related
- 2010-10-18 ES ES10765643.1T patent/ES2531986T3/es active Active
- 2010-10-18 WO PCT/EP2010/065579 patent/WO2011048032A1/en not_active Ceased
- 2010-10-18 EP EP10765643.1A patent/EP2491022B1/en not_active Not-in-force
- 2010-10-18 MX MX2012004112A patent/MX2012004112A/es active IP Right Grant
- 2010-10-18 KR KR1020127012920A patent/KR20120070609A/ko not_active Abandoned
- 2010-10-18 BR BR112012009661A patent/BR112012009661A2/pt not_active IP Right Cessation
- 2010-10-18 JP JP2012534641A patent/JP5654027B2/ja not_active Expired - Fee Related
- 2010-10-18 IN IN3045DEN2012 patent/IN2012DN03045A/en unknown
-
2012
- 2012-03-22 IL IL218795A patent/IL218795A0/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1871222A (zh) * | 2003-10-24 | 2006-11-29 | 霍夫曼-拉罗奇有限公司 | Ccr3受体拮抗剂 |
| WO2005123697A1 (ja) * | 2004-06-21 | 2005-12-29 | Astellas Pharma Inc. | キナゾリン誘導体 |
| WO2009010429A2 (en) * | 2007-07-19 | 2009-01-22 | F. Hoffmann-La Roche Ag | Novel heterocyclyl compounds and their use as chemokine antagonists |
Non-Patent Citations (1)
| Title |
|---|
| "Synthesis and initial evaluation of [11C](R)-RWAY in monkey-a new,simply labeled antagonist radioligand for imaging brain 5-HT1A receptors with PET";Julie A.McCarron et al.;《Eur.J.Nucl.Med.Mol.Imaging.》;20070620;第34卷;1670-1682 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120070609A (ko) | 2012-06-29 |
| EP2491022B1 (en) | 2014-12-31 |
| BR112012009661A2 (pt) | 2016-05-17 |
| US20110092698A1 (en) | 2011-04-21 |
| MX2012004112A (es) | 2012-05-08 |
| WO2011048032A1 (en) | 2011-04-28 |
| US8445674B2 (en) | 2013-05-21 |
| JP2013508328A (ja) | 2013-03-07 |
| JP5654027B2 (ja) | 2015-01-14 |
| AU2010309920A1 (en) | 2012-06-07 |
| CN102762541A (zh) | 2012-10-31 |
| ES2531986T3 (es) | 2015-03-23 |
| CA2776914A1 (en) | 2011-04-28 |
| IN2012DN03045A (enExample) | 2015-07-31 |
| IL218795A0 (en) | 2012-06-28 |
| EP2491022A1 (en) | 2012-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102762541B (zh) | 作为趋化因子受体的调节剂的二氮杂*衍生物 | |
| US8063042B2 (en) | Heterocyclic compounds | |
| BRPI0215158B1 (pt) | Compounds derived from pyrrolidine and piperidine as antagonists of nk1, pharmaceutical composition and use thereof | |
| CN101472904A (zh) | 趋化因子受体的二氮杂环庚烷衍生物调节剂 | |
| CN101679241B (zh) | 作为nk3拮抗剂的脯氨酰胺衍生物 | |
| JP5368556B2 (ja) | 心臓血管疾患の処置のための新規ヘテロシクリル化合物 | |
| JP5389917B2 (ja) | ケモカインレセプターのジアゼパン及びピペラジン誘導体モデュレーター | |
| CN102574858B (zh) | 双环杂环及其作为ccr2受体拮抗剂的用途 | |
| US20090227601A1 (en) | Bradykinin 1 Receptor Antagonists | |
| CN121152784A (zh) | 新型化合物，包含其的组合物及其用途 | |
| EA049144B1 (ru) | ФАРМАКОЛОГИЧЕСКИ АКТИВНЫЕ ЗАМЕЩЕННЫЕ ПО ГЕТЕРОЦИКЛИЧЕСКОМУ ФРАГМЕНТУ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА | |
| HK1175785A1 (zh) | 作为血管升压素拮抗剂的芳基-/杂芳基-环己烯基-四氮杂苯并[e]薁 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160316 Termination date: 20161018 |